BiotechTube

Empasiprubart IV

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dermatomyositis

Conditions

Dermatomyositis, Myositis

Trial Timeline

Aug 20, 2024 → Nov 1, 2026

NCT ID
NCT06284954

About Empasiprubart IV

Empasiprubart IV is a phase 2 stage product being developed by Argenx for Dermatomyositis. The current trial status is active. This product is registered under clinical trial identifier NCT06284954. Target conditions include Dermatomyositis, Myositis.

What happened to similar drugs?

0 of 3 similar drugs in Dermatomyositis were approved

Approved (0) Terminated (1) Active (2)
🔄DazukibartPfizerPhase 3
❌human immunoglobulin G + PlaceboCSLPhase 3
🔄Lenabasum 20 mg + Lenabasum 5 mg + PlaceboCorbus PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07091630Phase 3Recruiting
NCT06284954Phase 2Active

Competing Products

14 competing products in Dermatomyositis

See all competitors
ProductCompanyStageHype Score
tacrolimusAstellas PharmaPre-clinical
26
M5049 high dose + PlaceboMerckPhase 2
27
BAF312 + PlaceboNovartisPhase 2
27
MEDI7734 + PlaceboAmgenPhase 1
29
Etanercept + PlaceboAmgenPhase 1
29
DazukibartPfizerPhase 3
47
Anti-Beta Interferon (PF-06823859)PfizerPhase 2
35
PF-06823859 low + Placebo Arm + PF-06823859 highPfizerPhase 2
35
TofacitinibPfizerPhase 1
29
EmapalumabSwedish Orphan BiovitrumPhase 2
42
human immunoglobulin G + PlaceboCSLPhase 3
32
GLPG3667 + PlaceboGalapagosPhase 2
33
Lenabasum 20 mg + Lenabasum 5 mg + PlaceboCorbus PharmaceuticalsPhase 3
30
JBT-101 + PlaceboCorbus PharmaceuticalsPhase 2
17